Evidence map›Paper›PMID 34130296›Full record

SynthesisBlood purification2022

Incidence and Outcomes of Acute Kidney Injury in COVID-19: A Systematic Review.

Rupesh Raina, Zubin A Mahajan, Prabhav Vasistha, Ronith Chakraborty, Krishna Mukunda, Abhishek Tibrewal, Javier A Neyra

Abstract readSystematic Review
PubMed Full text at PMC Publisher
In one paragraph

Synthesis in Blood purification, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
25citing papers in PubMed, 2 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

25 citing papers in PubMed, 2 syntheses or guidelines pooled it.

  1. Pooled it
  2. Pooled it
  3. Review
  4. Observational
  5. Article
  6. Review
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Acute kidney injury among hospitalised patients who died due to COVID-19 in the Eastern Cape, South Africa.South African family practice : official journal of the South African Academy of Family Practice/Primary Care · 2023
    Article
  14. Review
  15. Article
  16. Article
  17. Article
  18. Article
  19. Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Rupesh RainaDepartment of Nephrology, Akron Nephrology Associates/Cleveland Clinic Akron General, Akron, Ohio, USA.
Zubin A MahajanDepartment of Nephrology, Akron Nephrology Associates/Cleveland Clinic Akron General, Akron, Ohio, USA.
Prabhav VasisthaDepartment of Nephrology, Akron Nephrology Associates/Cleveland Clinic Akron General, Akron, Ohio, USA.
Ronith ChakrabortyDepartment of Nephrology, Akron Nephrology Associates/Cleveland Clinic Akron General, Akron, Ohio, USA.
Krishna MukundaAkron Nephrology Associates/Cleveland Clinic Akron General, Akron, Ohio, USA.
Abhishek TibrewalDepartment of Nephrology, Akron Nephrology Associates/Cleveland Clinic Akron General, Akron, Ohio, USA.
Javier A NeyraDivision of Nephrology, Bone and Mineral Metabolism, University of Kentucky Medical Center, Lexington, Kentucky, USA.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

BACKGROUND AND

objectivesThe recent worldwide pandemic of COVID-19 has been a serious, multidimensional problem that has left a detrimental worldwide impact on individuals of all ages and several organ systems. The typical manifestation of kidney involvement is acute kidney injury (AKI); however, there is a lack of consensus data regarding AKI epidemiology in COVID-19. This systematic literature review aims to bridge this knowledge gap. DESIGN, SETTING, PARTICIPANTS, AND MEASUREMENTS: MEDLINE and Cochrane library were systematically searched for the literature related to AKI in COVID-19 patients of all ages. MedRxIV was searched for relevant unpublished manuscripts. Two reviewers independently assessed the literature on the incidence of AKI and mortality, extracting the need for kidney replacement therapy (KRT).

resultsSixty studies (n = 43,871 patients) were included in this review. The pooled incidence of AKI among COVID-19 patients was 19.45% (95% confidence intervals [95% CI]: 14.63-24.77%), while the pooled incidence of AKI COVID-19 patients requiring KRT was 39.04% (16.38-64.57%). The pooled proportion of COVID+ patients was significantly lower at 8.83% (5.64% to 12/66%). The overall mortality of COVID-19 patients was calculated to be 17.71% (95% CI: 11.49-24.93%), while the mortality among patients with AKI was higher at 54.24% (95% CI: 44.70-63.63%).

conclusionThis comprehensive systematic review summarizes the available literature pertaining to AKI epidemiology in COVID-19 patients and highlights the incidence, associated mortality, and the need for KRT in this susceptible population.

Indexed as

Acute Kidney InjuryCOVID-19Renal Replacement TherapySARS-CoV-2HumansIncidenceAcute kidney injuryCOVID-19EpidemiologyKidney replacement therapyNephrology

Identifiers

PMID34130296
PMCPMC8339045

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.